Approval of Baclofen for Alcohol Use Disorders in France: A Perspective From the United States
Clicks: 228
ID: 269204
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
228 views
28 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #3 of 4 articles by views in alcohol and alcoholism
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The recent approval of baclofen for the treatment of alcohol use disorders (AUDs) in France is notable as baclofen is now the sixth chemical entity (disulfiram,
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (26 words).
Try re-searching for a better abstract.
| Reference Key |
c2020alcoholapproval
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Garbutt, James C; |
| Journal | alcohol and alcoholism |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
female
male
United States
meta-analysis as topic
france
baclofen / therapeutic use*
alcoholism / drug therapy*
gaba-b receptor agonists / therapeutic use
pmid:31761948
doi:10.1093/alcalc/agz084
james c garbutt
drug approval*
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.